The Motley Fool··Andy GouldMajor Shareholder Trims $7.8M Harrow Stake, Signals Profit-Taking Over Retreat
Opaleye Management sold $7.8M in $HARR shares while retaining 10% stake, suggesting tactical rebalancing rather than loss of confidence in ophthalmic pharma company.
HROWearnings missportfolio rebalancing